Progyny, Inc.
In the published model solve dated 2026-Q2, anchored at $31.34, Progyny, Inc. (PGNY) is priced for today's economics sustained for ~5.3 years. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed June 28, 2026 from SEC EDGAR filings.
• Progyny sells fertility benefits to large employers, providing self-insured enterprise clients and their members with fertility coverage through a managed clinic network, and it has grown to more than ⟦"530 employers, each with at least 1,000 covered lives"⟧ across roughly 6.7 million lives. • The business is profitable and self-funded, holding about $225 million in net cash with no debt, and it has been shrinking its share count, retiring 8.8 million shares under a completed $200 million buyb
Is PGNY overvalued? See what's priced in →
281 institutional managers reported holding PGNY in 13F filings for the quarter ended 2026-03-31. Together they hold about 82% of the company; the top 10 hold 44%. 35 opened new positions that quarter. Held by BlackRock, FMR (Fidelity), State Street, among others. On the short side, 4.8M shares were sold short as of the 2026-06-15 count, about 6% of shares outstanding (3.4 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
PGNY has cut its share count 8.2% over the past five years, spending $500.54M on repurchases. It pays no dividend. Cash returned over the past three years: $500.54M in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at PGNY over the trailing three years: 2024: 2 buys totaling $5.24M; 2025: 1 buy totaling $1.93M. 13 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
PGNY's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-05 | +4.9% | -21.7% |
| 2023-11-09 | -4.3% | +27.9% |
| 2024-03-01 | -13.1% | -11.9% |
| 2024-05-11 | -14.4% | +5.2% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
PGNY's latest 8-K filings: 2026-08-06 (items 2.02, 7.01); 2026-05-27 (items 5.03, 5.07); 2026-05-26 (items 8.01); 2026-05-07 (items 2.02, 7.01); 2026-03-13 (items 8.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: June 28, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.